共查询到20条相似文献,搜索用时 0 毫秒
1.
Doxifluridine combined with weekly paclitaxel for second-line treatment in patients with gastric cancer resistant to TS-1 总被引:3,自引:0,他引:3
Arai W Hosoya Y Hyodo M Haruta H Kurashina K Saito S Hirashima Y Yokoyama T Zuiki T Sakuma K Yasuda Y Nagai H 《International journal of clinical oncology / Japan Society of Clinical Oncology》2007,12(2):146-149
Background Many patients with gastric cancer respond to TS-1, but some fail to respond or have recurrence. Second-line therapy is needed.
Methods We performed a pilot study in patients with advanced gastric cancer who did not respond to TS-1 or who had disease recurrence.
The patients received oral doxifluridine (600 mg/day) on days 1 to 21 and an intravenous infusion of paclitaxel (70 mg/m2) on days 7, 14, and 21 of a 28-day cycle. The treatment was repeated until disease progression or prohibitive toxicity. Response
rate, duration of response, median survival time (MST), effects on pleural effusion, ascites, and other signs, and toxicity
were evaluated.
Results The study group comprised 52 patients. The response rate was 28%. The duration of response was 103 days. The MST after the
start of second-line treatment was 175 days (95% confidence interval, 135 to 224 days). Pleural effusion or ascites resolved
or decreased in 73% of the patients. Hair loss occurred in 32 patients (62%), and leukopenia developed in 28 (54%, grade 3
in 1 patient and grade 2 or lower in the others). The MST after the start of treatment with TS-1 was about 16 months.
Conclusion A combination of doxifluridine and weekly paclitaxel is expected to be an effective second-line treatment for gastric cancer
not responding to TS-1, especially in patients with malignant ascites or pleural effusion. However, it remains unclear whether
paclitaxel plus doxifluridine results in a better response and survival benefit than paclitaxel alone in this subgroup of
patients. Further studies are therefore necessary. 相似文献
2.
Mizutani S Oyama T Hatanaka N Uchikoshi F Yoshidome K Tori M Ueshima S Nakahara M Nakao K 《International journal of clinical oncology / Japan Society of Clinical Oncology》2006,11(6):471-474
We report a 72-year-old man who was diagnosed by gastroscopy as having a type III poorly differentiated adenocarcinoma in
the lesser curvature, with the longest diameter being 10 cm. An abdominal computed tomography (CT) scan revealed multiple
liver metastases, thickening of the gastric wall, and an enlarged paraaortic lymph node. The serum carcinoembryonic antigen
(CEA) level was 60 ng/ml and the carbohydrate antigen (CA) 19–9 level was 1355 U/ml. The patient received combined chemotherapy
with doxifluridine (800 mg/body per day) and paclitaxel (one course comprised three weekly infusions at a dose of 70 mg/m2 followed by 1-week rest). After the completion of three courses, the patient achieved a complete response (CR), with complete
disappearance of the primary tumor, the metastatic foci in the liver, and the enlarged abdominal lymph nodes; as well, the
tumor markers were normalized. Adverse effects included only mild anorexia that was limited to grade 1. He maintained a CR
for 1 year and 2 months. Combination chemotherapy with paclitaxel and doxifluridine can be an effective treatment for unresectable
advanced gastric carcinoma. 相似文献
3.
目的:探讨胸苷磷酸化酶(TP)在胃癌中的表达及临床意义。方法:采用免疫组织化学法检测204例胃癌患者肿瘤组织中TP的表达,并探讨与临床病理因素、术后辅助化疗和预后之间的关系。结果:胃癌组织TP表达阳性率为47.1%。TP阳性表达患者中位生存时间为30.94个月,TP阴性表达患者为34.43个月,两者比较有显著的统计学差异(P=0.002)。TP阳性表达与患者年龄、发病部位、TNM分期、浸润深度、淋巴结转移等病理因素以及与以氟尿嘧啶为主的辅助化疗的疗效无明显相关性。结论:TP表达与胃癌患者长期生存有一定的相关性,有可能成为预测胃癌预后的一个参考指标。 相似文献
4.
Terashima M Fujiwara H Takagane A Abe K Araya M Irinoda T Yonezawa H Nakaya T Oyama K Takahashi M Saito K 《European journal of cancer (Oxford, England : 1990)》2002,38(18):2375-2381
This study was designed to investigate the role of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) on tumour progression and sensitivity to 5′-deoxy-5-fluorouridine (5′-DFUR). Tumour tissue was obtained from surgically resected samples from 93 patients with primary gastric cancer. Tumour TP and DPD expression levels were determined by the enzyme-linked immunosorbent assay (ELISA) system and compared with several clinicopathological factors and in vitro sensitivity to 5′-DFUR. DPD showed no correlation with any clinicopathological factors. However, the TP level was significantly correlated with the depth of tumour, lymphatic invasion and venous invasion. In comparison with 5′-DFUR sensitivity, there was a weak inverse correlation between the DPD level and the sensitivity to 5′-DFUR (rs=−0.361). Furthermore, the TP/DPD ratio showed a significant correlation with 5′-DFUR sensitivity (rs=0.634). In a subgroup of patients with postoperative 5′-DFUR administration, the survival rate was significantly better in patients with a high TP/DPD ratio (n=8) than in those with low TP/DPD ratio (n=14) (P=0.0140). These results suggest that sensitivity to 5′-DFUR is predictable by measurement of both TP and DPD levels. 相似文献
5.
Chung HW Bang SM Park SW Chung JB Kang JK Kim JW Seong JS Lee WJ Song SY 《International journal of radiation oncology, biology, physics》2004,60(5):85-1501
PURPOSE: The objective of this study was to compare the efficacy and toxicity of gemcitabine-based concurrent chemoradiotherapy (CCRT) with paclitaxel-based CCRT in patients with locally advanced pancreatic cancer. METHODS AND MATERIALS: A total of 48 patients who had received no prior therapy were enrolled. The patients were treated with 4500 cGy radiation in 25 fractions over 5 weeks concomitant with gemcitabine 1000 mg/m(2)/week/intravenously (IV) and doxifluridine 600 mg/m(2)/day/by mouth (PO), or paclitaxel 50 mg/m(2)/week/IV and doxifluridine 600 mg/m(2)/day/PO. After a 4-week rest, the responses were evaluated and maintenance therapies (operation or chemotherapy) (gemcitabine 1000 mg/m(2)/week/IV and doxifluridine 600 mg/m(2)/day/PO) were conducted. RESULTS: The median survival was 12 months in the gemcitabine group vs. 14 months in the paclitaxel group. The response rate was 13.6% vs. 25%, and the median time to progression was 12 months vs. 12.5 months, respectively. The positive rate of the clinical benefit response was 59.1% vs. 41.7%, respectively. Toxicities were acceptable in both groups. CONCLUSION: In this trial, we demonstrated that the gemcitabine-based CCRT and the paclitaxel-based CCRT in combination of doxifluridine are clearly acceptable treatment strategy, and appear more effective than the 5 fluorouracil-based CCRT for locally advanced pancreatic cancer with comparable tolerability. Furthermore, the paclitaxel-based CCRT showed similar efficacy and toxicities to the gemcitabine-based treatment when it was combined with 5-fluorouracil. 相似文献
6.
Kim JG Sohn SK Song HS Kwon KY Do YR Lee KH Hyun MS Ryoo HM Bae SH Park KU Baek JH Lee WS Chung JS Cho GJ Sohn CH Jang JS Chung HY Yu W 《Cancer chemotherapy and pharmacology》2007,60(6):863-869
Purpose Since a weekly administration of paclitaxel has demonstrated a sustained efficacy and more favorable toxicity profile than
a 3-weekly administration for various solid tumors, the present study was conducted to evaluate the efficacy and safety of
a combination regimen of weekly paclitaxel plus cisplatin in patients with advanced gastric cancer.
Patients and methods Patients with previously untreated metastatic or recurrent, measurable gastric cancer received intravenous paclitaxel 100 mg/m2 plus cisplatin 35 mg/m2 on days 1 and 8 based on a 3-week cycle.
Results Fifty-two patients were enrolled in the current study. Two complete responses and 17 partial responses were confirmed, giving
an overall response rate of 36.5%. At a median follow-up of 8.5 months, the median time to progression and median overall
survival was 6.0 and 10.8 months, respectively. Grade 3 neutropenia occurred in ten patients, while no grade 4 neutropenia
or febrile neutropenia was observed. The most common non-hematologic toxicity was nausea (grade 1/2, 56.9%). There were no
treatment-related deaths.
Conclusion A weekly paclitaxel and cisplatin combination was found to be well-tolerated and effective in patients with advanced gastric
cancer. Accordingly, this regimen can be regarded as an important first-line treatment option for advanced gastric cancer. 相似文献
7.
《Annals of oncology》2011,22(12):2575-2581
BackgroundSRC plays an important role in the pathogenesis of metastatic breast cancer (MBC). In preclinical models, paclitaxel and the oral SRC inhibitor dasatinib showed greater antitumor activity than either agent. To determine the maximum tolerated dose of this combination, we conducted a phase I study.Patients and methodsPatients with MBC; Eastern Cooperative Oncology Group performance status of zero to one; normal hepatic, renal and marrow function were eligible. Paclitaxel 80 mg/m2 was given 3 weeks of 4. The starting dasatinib dose was 70 mg and was increased, using a standard 3 + 3 dose-escalation scheme.ResultsFifteen patients enrolled (median age 54 years, range 35–74). No dose-limiting toxic effects (DLTs) occurred at dasatinib doses of 70–120 mg. One DLT (grade 3 fatigue) occurred in the dasatinib 150-mg cohort, which was expanded (six patients) with no further DLTs. However, due to cumulative toxic effects (rash, fatigue, diarrhea), the recommended phase II dose is dasatinib 120 mg. Of 13 assessable patients, a partial response was seen in 4 patients (31%), including 2 patients previously treated with taxanes; all received ≥120 mg dasatinib. An additional five patients (29%) had stable disease.ConclusionIn combination with weekly paclitaxel, the recommended phase II dose of dasatinib is 120 mg daily and preliminary activity has been seen in patients with MBC. 相似文献
8.
9.
Kato T Mishima H Ikenaga M Murata K Ishida H Fukunaga M Ota H Tominaga S Ohnishi T Amano M Ikeda K Ikeda M Sekimoto M Sakamoto J Monden M 《Cancer chemotherapy and pharmacology》2008,61(2):275-281
The purpose of this study was to examine the efficacy of a combination treatment of sequential irinotecan and doxifluridine,
an intermediate of capecitabine, evaluated by the response rate and safety in patients with metastatic colorectal cancer.
In all, 60 metastatic colorectal cancer patients with measurable disease were enrolled. The schedule of the treatment consisted
of a 90 min intravenous (IV) infusion of irinotecan 150 mg/m2 for on days 1 and 15, and 600–1,000 mg/body of oral doxifluridine on days 3–14 and 17–28. Cycles were repeated every 35 days.
A median of three cycles of the combination therapy (range 1–14 cycles) was administered. A total of 57 patients (95%) completed
at least two cycles of the therapy without any dose reductions. There was one complete response and 23 partial responses with
an overall response rate of 40% [95% confidence interval (CI): 28–53%]. A total of 19 patients had stable disease, 43(72%)
achieved disease control. The median time to progression was 5.9 months and the median overall survival was 20.5 months. Ten
(17%) and 17 (28%) patients developed Grade 3–4 leukopenia and neutropenia, respectively. Grade 3–4 fatigue was observed in
7(12%) patients, nausea in five (8%), vomiting in four (7%), and diarrhea,in three (5%) patients. No treatment-related deaths
were noted during the study. From these results, the combination of sequential irinotecan and doxifluridine is considered
to be an effective, easy-to-administer regimen with acceptable tolerability. 相似文献
10.
K Shitara S Yuki D Tahahari M Nakamura C Kondo T Tsuda T Kii Y Tsuji S Utsunomiya D Ichikawa A Hosokawa A Ishiguro D Sakai S Hironaka I Oze K Matsuo K Muro 《British journal of cancer》2014,110(2):271-277
Background:
This randomised phase II trial compared dose-escalated weekly paclitaxel (wPTX) vs standard-dose wPTX for patients with previously treated advanced gastric cancer (AGC).Methods:
Ninety patients were randomised to a standard dose of wPTX (80 mg m−2) or an escalated dose of wPTX (80–120 mg m−2) to assess the superiority of overall survival (OS) with a one-sided alpha error of 0.3 and a power of 0.8.Results:
The median OS showed a trend towards longer survival in the dose-escalated arm (11.8 vs 9.6 months; hazard ratio (HR), 0.75; one-sided P=0.12), although it was statistically not significant. The median progression-free survival (PFS) was significantly longer in the dose-escalated arm (4.3 vs 2.5 months, HR, 0.55; P=0.017). Objective response rate was 30.3% with dose escalation and 17.1% with standard dose (P=0.2). The frequency of all grades of neutropenia was significantly higher with dose escalation (88.7% vs 60.0%, P=0.002); however, no significant difference was observed in the proportion of patients experiencing grade 3 or more (40.9% vs 31.1%, P=0.34).Conclusion:
Dose-escalated wPTX in patients with pretreated AGC met our predefined threshold of primary end point, OS (P<0.3); however, it did not show a significantly longer OS. Progression-free survival was significantly better with dose escalation. 相似文献11.
Hyodo I Nishina T Moriwaki T Endo S Terao T Hirao K Nasu J Hirasaki S Endo H Masumoto T Tajiri H Kurita A 《European journal of cancer (Oxford, England : 1990)》2003,39(16):2328-2333
A dose-escalation study was conducted for patients with metastatic gastric cancer to determine the recommended dose of weekly intravenous (i.v.) cisplatin combined with a fixed dose of a new oral dihydropyrimidine dehydrogenase-inhibitory fluoropyrimidine, S-1, on an outpatient basis. Secondary endpoints were to define the toxicity profile and to determine tumour responses. S-1 was fixed at a dose of 70 mg/m(2)/day and was administered for 2 weeks followed by a 1-week rest. Three dose levels of cisplatin (10, 15 and 20 mg/m(2)) were studied. Cisplatin was infused over 30 min on days 1 and 8. 20 patients were enrolled. No dose-limiting toxicities (DLTs) were recorded during the administration of cisplatin up to 20 mg/m(2), except for grade 3 diarrhoea and stomatitis in one patient at dose level 3. No grade 4 adverse events occurred. However, grade 2 gastrointestinal adverse reactions, such as nausea and anorexia, were seen in 7 of 13 patients at dose level 3 within the first two treatment cycles. This was determined to be the maximum acceptable level that would not negate the advantages observed with use of an oral drug such as S-1. An objective tumour response was seen at all dose levels, and the overall response rate in the 18 patients evaluated was 61%. A higher response rate of 78% was observed in 9 patients who had received no prior chemotherapy. Oral S-1 with weekly cisplatin is a feasible and promising combination regimen that is appropriate for an outpatient setting. A randomised phase II study comparing this combination with S-1 alone in chemo-nai;ve patients is warranted. 相似文献
12.
Hokita S Aikou T Miyazono F Ishigami S Aridome K Maenohara S Saihara T Suenaga K Nomura H Maeda S Takatori H Arima H Uchikado Y Natsugoe S Takao S 《Cancer chemotherapy and pharmacology》2006,57(6):736-740
The aim of the current study was to determine the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of a combination
of paclitaxel and S-1 in patients with advanced gastric cancer. Fifteen patients were enrolled. The dose for S-1 was set at
80 mg/m2/day (days 1–14), while the dose for paclitaxel increased by 10 mg/m2 for every three patients, with a starting dose of 100 mg/m2 and was given biweekly on day 1 and 15. There was no severe toxicity (grade 4) recorded in patients receiving up to 120 mg/m2 of paclitaxel. Leukopenia/neutrophilia with grade 1 to 3 occurred in six patients up to level 3. At 130 mg/m2 of paclitaxel, grade 4 leukocytopenia and neutropenia events and grade 3 diarrhea developed in one out of three patients.
One patient in another group of three patients that were enrolled at level 3, developed grade 4 granulocytopenia with fever
(a body temperature higher than 38°C) and grade 3 leukocytopenia. Eight patients, out of a total of 15, showed a partial response,
resulting in an objective response rate of 53%. Five patients received gastrectomy. Median survival time was 428 days and
the 1 year survival rate was 53%. Biweekly paclitaxel/S-1 combination chemotherapy could be safely used for the treatment
of advanced gastric cancer. The recommended doses for a phase II study with paclitaxel and S-1 are 120 mg/m2 and 80 mg/m2, respectively. 相似文献
13.
目的 观察紫杉醇联合卡培他滨一线治疗晚期胃癌的疗效和毒副反应。方法 晚期胃癌患者20例,给予紫杉醇80mg/m2静脉滴注,第1、8天;卡培他滨1000mg/m2,分早晚各口服1次,第1~14天;21天为1周期。每2周期评价疗效。结果 19例可评价疗效,获CR1例,PR7例,总有效率(RR)为42.1%。中位无进展生存期和总生存期分别为4.8个月和9.7个月,1年生存率为36.8%。主要的毒副反应为血液学毒性、脱发和手足综合症。结论 紫杉醇联合卡培他滨治疗晚期胃癌安全、有效,值得临床进一步应用。 相似文献
14.
Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer
Wada Y Kikuchi K Takahashi W Honda J Nakanishi J Matsumoto K Kuwahara T Kai N Kikukawa H Ueda S 《Cancer chemotherapy and pharmacology》2008,61(1):53-61
Purpose Advanced prostate cancer, which is one of the most common cancers, usually progresses to hormone-refractory prostate cancer
(HRPC).
A recent randomized trial of treatment with docetaxel demonstrated improved survival for patients with HRPC. The combination
of docetaxel and estramustine phosphate (estramustine) has been reported to be effective for HRPC. Low-dose estramustine suppresses
the pituitary–gonadal axis. Docetaxel plus 5-fluoro-5′-deoxyuridine (5′-dFUrd) had supra-additive cytotoxic effects on HRPC
cells consistent with the molecular mechanism. Therefore, we examined the efficacy of adding 5′-dFUrd on the chemotherapy
regimen, which consist docetaxel and estramustine.
Methods All of the HRPC patients were treated with estramustine 140 mg orally twice 5′-dFUrd 200 mg orally four times daily on days
1–21, and docetaxel 60 mg/m2 was administered on day 1.
We evaluated serum prostate-specific antigen (PSA) and measurable responses, the progression-free and overall survival, and
the impact on adverse effects and the quality of life (QOL).
Results Of 34 patients with a median age of 72.3 years, 73% showed PSA responses and 70% showed measurable responses. The median progression-free
survival was 18.0 and 5.8 months for PSA responders and non-responders and the overall survival was 19.4 months, respectively.
There were few serious adverse effects. Grade 3/4 neutropenia occurred in 32.4% of the patients, and was easily managed with
granulocyte colony-stimulating factor (G-CSF) injection. There was no significant change in the overall QOL scores serially.
Conclusions This study shows that the combined regimen is tolerable and effective in Japanese HRPC patients. 相似文献
15.
Tsubono M Kaneko I Kii E Murata T Kamimura K Deguchi Y Yasumizu R 《Gan to kagaku ryoho. Cancer & chemotherapy》2005,32(9):1283-1287
We designed a new regimen to evaluate the efficacy and feasibility of weekly paclitaxel combined with orally administered 5'-DFUR therapy against advanced and recurrent gastric cancer. Nine patients were enrolled. Weekly paclitaxel administration (PTX 60 mg/m2, 2 consecutive weeks, 1-week break) and oral administration of 5'-DFUR (460 mg/m2, 14 consecutive days) were performed on an ambulatory basis. This was repeated every 3 weeks until disease progression and/or severe toxic events occurred. The overall response rate was 44.4% with 22.2% complete response and 22.2% partial response in addition to 44.4% no changes beyond 3 months. In NC criteria, 3 patients showed clinical improvements, such as decreasing tumor markers, releasing from the ileus, and improvement of liver dysfunction. These results suggested that clinical benefits in 89% of patients. On the other hand, toxic events were restricted to grade 3 with 11.1% general fatigue and 11.1% appetite loss. Therefore, the weekly administration of PTX in conjunction with daily oral administration of 5'-DFUR therapy seems to be extremely useful, with excellent anti-tumor effect and tolerable adverse reactions for the treatment of recurrent gastric cancer on an ambulatory basis. 相似文献
16.
Hara T Omura K Hirano M Asada Y Munemoto Y Sakamoto J 《Cancer chemotherapy and pharmacology》2007,59(5):631-636
Purpose
A phase I study of TCF therapy, which consists of paclitaxel (TXL: Taxol®) + cisplatin (CDDP) + 5-fluorouracil (5-FU), in advanced gastric cancer patients was performed to determine the recommended dose (RD) for a phase II study by checking the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of 5-FU above the fixed dose of TXL and CDDP.Methods
The doses of TXL and CDDP were fixed at 80 and 25 mg/m2, respectively, while that of 5-FU was increased by 100 mg/m2 in each cohort from 300 mg/m2 (level 1) to a maximum of 600 mg/m2 (level 4). One cycle consisted of administration of these agents once per week for 3 weeks, every 4 weeks.Results
A total of twelve eligible patients were included in this study. At level 1, two of three cases showed grade 3 leukopenia. At level 2, one of three cases showed grade 4 neutropenia (recovered within 3 days), and another one case showed grade 3 neutropenia. At level 3, one of three cases showed grade 3 neutropenia, and at level 4, one of three cases showed grade 4 neutropenia (recovered within 3 days), with grade 3 neutropenia in the other two cases. Even at the highest dose administered, none of the patients showed DLT. Moreover, no non-hematological toxicity judged to be DLT was observed through all levels. Six of the twelve patients had measurable disease, and the overall response rate was 83%.Conclusions
Although the MTD level was not determined, based on the observed efficacy and the results of other clinical trials, the recommended doses of TXL, CDDP, and 5-FU for the TCF regimen were set as 80, 25, and 600 mg/m2, respectively, and a phase II study to investigate the clinical effectiveness and safety of this regimen has now begun. 相似文献17.
Kokufu I Kimura F Tanei T Taniguchi H Fukuda K Yamamoto M Yano T Yamada K 《Gan to kagaku ryoho. Cancer & chemotherapy》2003,30(8):1165-1168
We report a case of long-term effectiveness of weekly paclitaxel (TXL) administration for metastatic gastric cancer. TXL (80 mg/m2) was infused over 1 hour after short premedication on an outpatient basis. Administration was continued for 3 weeks followed by 1 week rest. A 61-year-old man was diagnosed as having gastric cancer with multiple liver metastases. He was treated with FP therapy and irinotecan/cisplatin administration and both therapies were assessed to result in progressive disease. We attempted weekly TXL administration and assessed a long period of no change after 6 courses. The treatment is ongoing. The toxic events were peripheral neuropathy and alopecia (grade 2), with no episodes of leukopenia, nausea and vomiting. The patient's quality of life was fair during the treatment. Weekly TXL administration is a useful treatment for metastatic gastric cancer. 相似文献
18.
Atsushi Sato Ken Shimada Masatoshi Nakamachi Jun Ushio Wataru Yamamoto Minoru Kurihara Masaaki Matsukawa 《Gastric cancer》2002,5(4):0233-0236
A 58-year-old man was diagnosed as having type 3 gastric cancer (poorly differentiated adenocarcinoma). He underwent total
gastrectomy with splenectomy, as well as D3 dissection, and received postoperative chemotherapy combining oral uracil and
futrafur (UFT) with cisplatin (CDDP), but results showed recurrence of multiple abdominal lymph node metastases around the
aorta. He therefore received various anticancer drug regimens (irinotecan [CPT-11]/CDDP; 1 M tegafur-0.4 M gimeracil-1 M oteracil
potassium [TS-1], methotrexate (MTX)/5-fluorouracil); however, final results showed growth of lymph node metastasis and simultaneous
worsening of his general condition. The patient then received combined administration of doxifluridine (5′-DFUR)/docetaxel
(5′-DFUR, 1000 mg/body [666.7 mg/m
2
], given by consecutive daily administration, orally, for days 1–14; and docetaxel, 80 mg/body [60 mg/m
2
], on day 8, by venous drip, every 3 weeks). Three courses of this regimen resulted in approximately 90% reduction of the
abdominal lymph node size, disappearance of the right cervical lymph node metastasis, reductions of the levels of two tumor
markers (carcinoembryonic antigen [CEA] and carbohydrate antigen [CA]19-9), and improvement of his general condition. In total,
seven courses of the regimen were carried out. The patient died on day 298 after starting this combined regimen and showed
a response period of 126 days. The primary toxicity identified was neutropenia (grade 4), as well as other low-grade (grade
1, 2) hematological and nonhematological toxicities. In the field of gastric cancer treatment, especially for patients showing
multiple resistance to anticancer drugs, an effective therapy is critically needed.
Received: January 15, 2002 / Accepted: July 8, 2002
Offprint requests to: A. Sato 相似文献
19.
Kokufu I Tanei T Taniguchi H Kimura F Fukuda K Yamamoto M Yano T Yamada K 《Gan to kagaku ryoho. Cancer & chemotherapy》2002,29(11):2005-2008
We report a case of effective weekly paclitaxel (TXL) administration for metastatic gastric cancer. TXL (80 mg/m2) was infused over 1 hour after short premedication on an outpatient basis. Administration was continued for 3 weeks followed by 1 week rest. A 74-year-old man was diagnosed with recurrence 49 months after surgery for gastric cancer. He was treated with 5-fluorouracil and cisplatin, and thrombocytopenia (grade 3) and creatinin elevation (grade 1) were observed and assessed as progressive disease 2 months after the treatment. We attempted weekly TXL administration and after 5 courses assessed the patient as having a partial response. The treatment is ongoing. The toxic event was leukopenia (grade 2), with no episode of thrombocytopenia. The patient did not complain of nausea or vomiting, and his quality of life was fair during the treatment. Weekly TXL administration is a useful treatment for metastatic gastric cancer. 相似文献
20.
Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan 总被引:1,自引:1,他引:0
Michiya Kobayashi Koji Oba Junichi Sakamoto Ken Kondo Naoki Nagata Takehiro Okabayashi Tsutomu Namikawa Kazuhiro Hanazaki 《Gastric cancer》2007,10(1):52-57
Background We aimed to clarify the relationship between the maximum tolerated dose and plasma concentration of paclitaxel in Japanese
patients with gastric cancer on a weekly paclitaxel administration regimen.
Methods Thirty-three patients with advanced or recurrent gastric cancer were treated with escalating doses of paclitaxel, administered
weekly, along with a fixed dose of 5-fluorouracil or cisplatin.
Results The plasma concentration of paclitaxel remained above 8.5 ng/ml for 24 h after administration. The mean area under the curve
increased significantly with escalating dosage levels (R = 0.63; P 0.001). At level 4, patients showing dose-limiting toxicity had a significantly higher plasma paclitaxel concentration than
patients without it.
Conclusion The weekly administration of paclitaxel, for which a single dose is about one-third of the dose for a tri-weekly treatment
regimen, is clinically feasible and appropriate in terms of toxicity and the maintenance of an effective plasma concentration. 相似文献